Učitavanje...
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3018944/ https://ncbi.nlm.nih.gov/pubmed/20716591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq099 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|